Patents Assigned to Aqtual, Inc.
  • Methods for characterizing cell-free nucleic acid fragments
    Patent number: 11993818
    Abstract: The present disclosure provides methods and systems for various uses of cell-free nucleic acid (cfNA). Functional typing of cfNA fragmentation patterns may be utilized in the non-invasive detection, diagnosis, and monitoring of disease. One embodiment may determine a stage of cancer in a subject, the progression of cancer in a subject, or the responsiveness to treatment of a cancer in a subject. Another embodiment disclosed herein may include sequencing-free diagnostic methods.
    Type: Grant
    Filed: June 16, 2023
    Date of Patent: May 28, 2024
    Assignee: Aqtual, Inc.
    Inventor: Diana Abdueva
  • Methods for sequencing samples
    Patent number: 11965211
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: April 23, 2024
    Assignee: Aqtual, Inc.
    Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow